L3VLUP
ProSign in

LAB · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

LABJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • LAB
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterLABJNJ
Q3 20205 holders, $51m30 holders, $26.2bn
Q4 20204 holders, $13m32 holders, $26.6bn
Q1 20211 holders, $2.2m31 holders, $25.3bn
Q2 20211 holders, $1.2m37 holders, $25.6bn
Q3 20211 holders, $843k40 holders, $24.1bn
Q4 20211 holders, $585k33 holders, $25.2bn
Q1 2022none listed holders, n.a.35 holders, $28.2bn
Q2 2022none listed holders, n.a.33 holders, $26.9bn
Q3 2022none listed holders, n.a.36 holders, $25.4bn
Q4 2022none listed holders, n.a.35 holders, $27.6bn
Q1 2023none listed holders, n.a.42 holders, $24.5bn
Q2 2023none listed holders, n.a.38 holders, $25.0bn
Q3 2023none listed holders, n.a.37 holders, $18.9bn
Q4 2023none listed holders, n.a.31 holders, $19.0bn
Q1 20242 holders, $194m32 holders, $19.7bn
Q2 20242 holders, $126m35 holders, $20.4bn
Q3 20242 holders, $130m28 holders, $22.3bn
Q4 20242 holders, $108m37 holders, $20.4bn
Q1 20252 holders, $67m32 holders, $20.5bn
Q2 20252 holders, $74m31 holders, $18.4bn
Q3 20252 holders, $80m32 holders, $23.7bn
Q4 20252 holders, $79m29 holders, $27.8bn
Q1 20261 holders, $54m34 holders, $35.6bn
Q2 20261 holders, $48m33 holders, $39.1bn
LAB

Standard Biotools Inc

Holders
1
Reported value
$54m
Buyers
8
Sellers
4

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
34
Reported value
$35.6bn
Buyers
21
Sellers
18

Breadth +3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only LAB (1)

Viking Global Investors LP

Only JNJ (34)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, and 9 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →